Papillary Thyroid
Carcinoma
Papillary carcinoma is the most common form of well-differentiated
thyroid cancer.
Etiology And Pathogenesis:
Genetics play an important role in pathogenesis of Papillary
Thyroid Carcinoma of Thyroid.
Papillary thyroid carcinoma seems closely related to the
activation of the trk and ret proto-oncogenes, both acting by amplifying and
rearranging mechanisms
There is also a clear association between prior neck
irradiation and incidence of PTC.
Other predisposing
factors include the following:
Iodine deficiency
Oral contraceptive use
Benign thyroid nodules
Late menarche
Late age at first birth
Tobacco smoking
Patients with a history of Hashimoto thyroiditis are at
increased risk for papillary thyroid cancer.
Gender:
Thyroid cancer is approximately three times more common in
females than males.
Age:
Thyroid carcinoma is common in persons of all ages, with a
mean age of 49 years and an age range of 15-84 years.
Metastasis:
Papillary tumors have a propensity to invade lymphatics but
are less likely to invade blood vessels.
Clinical
Presentation:
The most common presentation of thyroid CANCER is an
asymptomatic thyroid mass or a nodule that can be felt in the neck.
For any patient with a thyroid lump that has developed
recently, record a thorough medical history to identify any risk factors or
symptoms.
In particular, obtain a history regarding every prior
exposure to ionizing radiation and the lifetime duration of the radiation
exposure.
Consider a family history of thyroid cancer.
Thyroid ca may present with following symptoms:
Persistent cough,
Difficulty breathing, or
Difficulty swallowing.
Pain is seldom an early warning sign of thyroid cancer.
Other symptoms (eg, pain, stridor, vocal cord paralysis,
hemoptysis, rapid enlargement) are rare, and can be caused by less serious
problems.
Metastasis:
At the time of diagnosis, 10-15% of patients with papillary
thyroid carcinoma have distant metastases to the bones and lungs. Initially,
these patients are evaluated for pulmonary or osteoarticular manifestations
(eg, pathologic fracture, spontaneous fracture).
Physical Examination
The clinician should palpate the patient's neck to evaluate
the size and firmness of the thyroid and to check for any thyroid nodules. The
principal sign of thyroid carcinoma is a palpable nodule, usually solitary, in
the thyroid area that has the following characteristics:
Painless
Hard consistency
Average size of less than 5 cm
Ill-defined borders
Fixed in respect to surrounding tissues
Moves with the trachea at swallowing
If cervical lymphadenopathy is present, it may be palpable
on either the ipsilateral or contralateral side.
Some patients have a tight or full feeling in the neck,
hoarseness, or signs of tracheal or esophageal compression.
Diagnosis:
The following workup should be considered for the diagnosis
of papillary carcinoma, a relatively common well-differentiated thyroid cancer:
Thyroid function studies
TSH suppression test
Thyroid ultrasound
Fine-needle aspiration biopsy (FNAB)
Procedures
FNAB is considered the best first-line diagnostic procedure
for a thyroid nodule.
Imaging studies
Thyroid Ultrasound
Thyroid ultrasound is the first imaging study to perform in
any patient with possible thyroid malignancy.
Ultrasound is noninvasive and
inexpensive, and it represents the most sensitive procedure for identifying
thyroid lesions and for determining the diameters of a nodule.
Ultrasound is also useful for localizing lesions when a
nodule is difficult to palpate or is deeply seated. The images can help determine
if a lesion is solid or cystic and can help detect the presence of
calcifications.
Ultrasound may be
used to help direct a fine-needle aspiration biopsy (FNAB).
Pulsed and power Doppler ultrasound may provide important
information about the vascular pattern and the velocimetric parameters.
Such information can
be useful preoperatively to reach a correct differential diagnosis of malignant
or benign thyroid lesion.
Scintigraphy
Before the advent of fine-needle aspiration biopsy (FNAB),
thyroid scintigraphy (or thyroid scanning) performed with technetium Tc 99m
pertechnetate (99mTc) or radioactive iodine (I131 or I123) was the initial
diagnostic procedure of choice for a thyroid evaluation.
Malignant nodules usually appear as cold because
they are not functioning.
Findings from thyroid scanning are helpful and specific in
the preoperative and immediate postoperative periods for localization of cancer
or residual thyroid tissue and in observing for tumor recurrence or metastasis.
Thyroid scanning can also be useful for diagnosing benign lesions (by FNAB) or
solid lesions (by echography).
Fine-Needle
Aspiration Biopsy
Fine-needle aspiration biopsy (FNAB) is considered the best
first-line diagnostic procedure for a thyroid nodule. FNAB is a safe and
minimally invasive procedure.
The accuracy of FNAB results is better than any other test
for detecting papillary thyroid carcinoma. The sensitivity of the procedure is
near 80%, the specificity is near 100%, and errors can be diminished using
ultrasonographic guidance.
Fine-needle aspiration biopsy (FNAB) is considered the best
first-line diagnostic procedure for a thyroid
nodule
Management
Surgery is the definitive management of papillary thyroid
cancer. Approximately 4-6 weeks after surgical thyroid removal, patients may have
radioiodine therapy to detect and destroy any metastasis and residual tissue in
the thyroid.
Lobectomy with isthmectomy is the minimal operation for a
potentially malignant thyroid nodule. It is an option for patients younger than
40 years who have papillary thyroid carcinoma nodules that are smaller than 1
cm, well-defined, minimally invasive, and isolated.
However, an important consideration in considering this
approach is that approximately 10% of patients who
have had only a lobectomy
develop a recurrence in the contralateral lobe, and residual tissue has the
potential to dedifferentiate to anaplastic cancer.
Subtotal thyroidectomy is a near-total thyroidectomy. The
argument for this form of surgical intervention is that total thyroidectomy
does not improve long-term prognosis, and subtotal thyroidectomy has a lower
incidence of complications (eg, hypoparathyroidism, superior and/or recurrent
laryngeal nerve injury) than total thyroidectomy.
Total thyroidectomy
Total thyroidectomy (removal of all thyroid tissue but
preservation of the parathyroid glands) is commonly performed for patients with
papillary carcinoma who are older than 40 years and in any patient with
bilateral disease. In addition, total thyroidectomy is used in most patients
with a thyroid nodule and a history of irradiation.
National Comprehensive Cancer Network guidelines recommend
total thyroidectomy for patients who meet any of the following criteria
Radiation history
Known distant metastases
Bilateral nodularity
Extrathyroidal extension
Tumor > 4 cm in diameter
Cervical lymph node metastases
Poorly differentiated tumor
Total thyroidectomy is considered by many to be the surgical
treatment of choice for papillary tumors of the thyroid, for a number of
reasons. Papillary foci involving both lobes are found in some 60-85% of
patients.
About 5-10% of patients who have had a lobectomy develop recurrences
in the remaining lobe. Also, at 20 years after initial surgery, patients who
had undergone total thyroidectomy had a recurrence rate of 8%, whereas those
who had received lobectomy only had a recurrence rate of 22%. Survival rates were,
however, comparable.
External beam radiotherapy has been used as adjuvant therapy
in patients with papillary thyroid cancer who were older than 45 years and had
locally invasive disease. Some improvements in 10-year survival rates have been
reported with this approach.
Patients require lifelong thyroid hormone replacement
therapy, especially after total thyroidectomy. Treatment consists of
levothyroxine in a dosage of 2.5-3.5 mcg/kg/d.
Surgical Care
Surgery is the definitive management of thyroid cancer.
Various types of operations may be performed, ranging from lobectomy with
isthmectomy to total thyroidectomy.
After thyroidectomy, patients are given thyroid replacement
therapy for approximately 4-6 weeks. Thyroid replacement is then discontinued,
to induce a hypothyroid state and promote high serum thyroid-stimulating
hormone (TSH) levels.
A diagnostic dose of radioiodine (131 I or123 I) is then
given, and a whole-body scintiscan is performed to detect any tissue taking up
radioiodine. If any normal thyroid remnant or metastatic disease is detected, a
therapeutic dose of131 I is administered to ablate the tissue. The patient is
then placed back on thyroid hormone replacement (levothyroxine) therapy.
Therapy is administered until radioiodine uptake is
completely absent. Radioiodine treatment may be used again 6-12 months after
initial treatment of metastatic disease, for cases in which disease recurs or
has not fully responded.
Prognosis
The prognosis of papillary thyroid cancer is related to age,
sex, and stage. In general, if the cancer does not extend beyond the capsule of
the gland, life expectancy is minimally affected. Prognosis is better in female
patients and in patients younger than 40 years. The survival rate is at least
95% with appropriate treatments.
Risk factors for
overall survival include the following:
Age older than 45 years
Male sex
Minority race
Node metastases
Extrathyroidal invasion
Distant metastases
If two or more risk factors are present, patients should be
considered for more aggressive management.
Staging
The staging of well-differentiated thyroid cancers follows
the tumor, node, metastasis (TNM) classification system. Staging differs,
depending on whether the patient is younger than 45 years of age.
Staging for patients younger than 45 years is as follows:
Stage I - Any T, any N, M0 (cancer in thyroid only)
Stage II - Any T, any N, M1 (cancer spread cervical lymph
nodes or to distant organs)
Staging for patients aged 45 years and older is as follows:
Stage I - T1, N0, M0 (cancer only in thyroid, and less than
2 cm)
Stage II - T2, N0, M0 and T3, N0, M0 (cancer only in thyroid
and between 2-4 cm)
Stage III - T4, N0, M0 and any T, N1, M0 (tumor greater than
4 cm or cancer spread outside thyroid but not outside of the central neck
compartment)
Stage IV - Any T, any N, M1 (cancer spread to either
cervical lymph nodes outside of the central neck or distant organs)
Differential
Diagnoses
Differential Diagnosis for Thyroid ca includes the following:
Anaplastic Thyroid Carcinoma
Follicular Thyroid Carcinoma
Goiter
Graves Disease
Hurthle Cell Carcinoma
Medullary Thyroid Carcinoma
Parathyroid Carcinoma
Thyroid Lymphoma
Thyroid Nodule